Login to Your Account

Clinic Roundup

Wednesday, October 16, 2013
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said the independent data monitoring committee overseeing the firm’s ongoing pivotal Phase III study of Firdapse (amifampridine phosphase) in Lambert-Eaton myasthenic syndrome (LEMS) recommended that the study continue as planned based on a review of safety and clinical data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription